Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase

C. Bartolucci, L. Cellai, M. Marzano, A. Segre, M. Brufani, L. Filocamo, A. D. Bianco, M. Guiso, V. Brizzi, A. Benedetto, A. Di Caro

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Three types of open ansa-chain rifamycin S derivatives have been prepared: derivatives with the ansa-chain open at C(29) and the original dihydrofuranone ring; derivatives with the ansa-chain open at C(29) and a furane ring; derivatives with the ansa-chain at open NH-C(15). Only derivatives of the first type are weak inhibitors of HIV-1 reverse transcriptase (IC50 ca. 300 μM) while derivatives of the two other types are inactive. It has been hypothesized that the active derivatives inhibit the viral enzyme interacting through the groups C(14)H3, C(13)H3, and C(1)O at the same site as the well-known inhibitors TIBO and Nevirapine. In particular C(13)H3 must be unhindered and in an appropriate position out of the plane containing the chromophore-rings. The open ansa-chain seems to play the role of a lipophylic substituent.

Original languageEnglish
Pages (from-to)587-593
Number of pages7
JournalFarmaco
Volume50
Issue number9
Publication statusPublished - 1995

Fingerprint

Nevirapine
Structure-Activity Relationship
Inhibitory Concentration 50
Enzymes
rifamycin S
Human immunodeficiency virus 1 reverse transcriptase

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmaceutical Science

Cite this

Bartolucci, C., Cellai, L., Marzano, M., Segre, A., Brufani, M., Filocamo, L., ... Di Caro, A. (1995). Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase. Farmaco, 50(9), 587-593.

Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase. / Bartolucci, C.; Cellai, L.; Marzano, M.; Segre, A.; Brufani, M.; Filocamo, L.; Bianco, A. D.; Guiso, M.; Brizzi, V.; Benedetto, A.; Di Caro, A.

In: Farmaco, Vol. 50, No. 9, 1995, p. 587-593.

Research output: Contribution to journalArticle

Bartolucci, C, Cellai, L, Marzano, M, Segre, A, Brufani, M, Filocamo, L, Bianco, AD, Guiso, M, Brizzi, V, Benedetto, A & Di Caro, A 1995, 'Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase', Farmaco, vol. 50, no. 9, pp. 587-593.
Bartolucci C, Cellai L, Marzano M, Segre A, Brufani M, Filocamo L et al. Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase. Farmaco. 1995;50(9):587-593.
Bartolucci, C. ; Cellai, L. ; Marzano, M. ; Segre, A. ; Brufani, M. ; Filocamo, L. ; Bianco, A. D. ; Guiso, M. ; Brizzi, V. ; Benedetto, A. ; Di Caro, A. / Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase. In: Farmaco. 1995 ; Vol. 50, No. 9. pp. 587-593.
@article{aaf5eff06c654b148f8ecc3c5655731f,
title = "Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase",
abstract = "Three types of open ansa-chain rifamycin S derivatives have been prepared: derivatives with the ansa-chain open at C(29) and the original dihydrofuranone ring; derivatives with the ansa-chain open at C(29) and a furane ring; derivatives with the ansa-chain at open NH-C(15). Only derivatives of the first type are weak inhibitors of HIV-1 reverse transcriptase (IC50 ca. 300 μM) while derivatives of the two other types are inactive. It has been hypothesized that the active derivatives inhibit the viral enzyme interacting through the groups C(14)H3, C(13)H3, and C(1)O at the same site as the well-known inhibitors TIBO and Nevirapine. In particular C(13)H3 must be unhindered and in an appropriate position out of the plane containing the chromophore-rings. The open ansa-chain seems to play the role of a lipophylic substituent.",
author = "C. Bartolucci and L. Cellai and M. Marzano and A. Segre and M. Brufani and L. Filocamo and Bianco, {A. D.} and M. Guiso and V. Brizzi and A. Benedetto and {Di Caro}, A.",
year = "1995",
language = "English",
volume = "50",
pages = "587--593",
journal = "Farmaco",
issn = "0014-827X",
publisher = "Societa chimica italiana",
number = "9",

}

TY - JOUR

T1 - Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase

AU - Bartolucci, C.

AU - Cellai, L.

AU - Marzano, M.

AU - Segre, A.

AU - Brufani, M.

AU - Filocamo, L.

AU - Bianco, A. D.

AU - Guiso, M.

AU - Brizzi, V.

AU - Benedetto, A.

AU - Di Caro, A.

PY - 1995

Y1 - 1995

N2 - Three types of open ansa-chain rifamycin S derivatives have been prepared: derivatives with the ansa-chain open at C(29) and the original dihydrofuranone ring; derivatives with the ansa-chain open at C(29) and a furane ring; derivatives with the ansa-chain at open NH-C(15). Only derivatives of the first type are weak inhibitors of HIV-1 reverse transcriptase (IC50 ca. 300 μM) while derivatives of the two other types are inactive. It has been hypothesized that the active derivatives inhibit the viral enzyme interacting through the groups C(14)H3, C(13)H3, and C(1)O at the same site as the well-known inhibitors TIBO and Nevirapine. In particular C(13)H3 must be unhindered and in an appropriate position out of the plane containing the chromophore-rings. The open ansa-chain seems to play the role of a lipophylic substituent.

AB - Three types of open ansa-chain rifamycin S derivatives have been prepared: derivatives with the ansa-chain open at C(29) and the original dihydrofuranone ring; derivatives with the ansa-chain open at C(29) and a furane ring; derivatives with the ansa-chain at open NH-C(15). Only derivatives of the first type are weak inhibitors of HIV-1 reverse transcriptase (IC50 ca. 300 μM) while derivatives of the two other types are inactive. It has been hypothesized that the active derivatives inhibit the viral enzyme interacting through the groups C(14)H3, C(13)H3, and C(1)O at the same site as the well-known inhibitors TIBO and Nevirapine. In particular C(13)H3 must be unhindered and in an appropriate position out of the plane containing the chromophore-rings. The open ansa-chain seems to play the role of a lipophylic substituent.

UR - http://www.scopus.com/inward/record.url?scp=0028807315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028807315&partnerID=8YFLogxK

M3 - Article

C2 - 7495468

AN - SCOPUS:0028807315

VL - 50

SP - 587

EP - 593

JO - Farmaco

JF - Farmaco

SN - 0014-827X

IS - 9

ER -